IS THERE A RELATIONSHIP BETWEEN SELENOPROTEIN P1 (SEPP1) GENE POLYMORPHISM AND GESTATIONAL DIABETES MELLITUS IN TURKISH WOMEN

Yıl 2017, Cilt: 3 Sayı: 1, 56 - 61, 30.03.2017

Ayşe Yücel Fatma Behice Cinemre Hakan Cinemre M. Aytaç Yüksel Abdullah Tüten Nevin Yılmaz Birsen Aydemir

Öz

Objective: Diabetes Mellitus (DM) is
a complex disease caused by a combination of genetic and environmental factors.
Selenoprotein P (SeP) appears to play a key role in the etiopathogenesis of DM.
Recently, it has been demonstrated that SeP played an important role in
glucose metabolism and the regulation of insulin sensitivity as a new
hepatokine. The purpose of this study was to
determine whether common variations in selenoprotein P1 (SEPP1) alter the risk
of Gestational Diabetes Mellitus (GDM).

Materials and Methods: 72 pregnant women with GDM and 64 healthy pregnant
women from the same geographic region were included in the study.
Allele-specific Polymerase Chain Reaction (ASPCR) analysis was used to identify
polymorphisms of the SEPP1 gene
(rs3877899).

Results: We found that fasting glucose, insulin, HOMA-IR, HbA1c, total
cholesterol levels and weight of fetus were higher in gestational diabetic
pregnants compared group to healthy pregnant women group. The frequencies of
the AA, GA and GG genotypes were found as 28 %, 43 % and 29 % in pregnant women
with GDM and 24 %, 50 % and 26 % in healthy pregnant women, respectively. Our
results indicated that the distribution of the SePP1 genotypes and alleles did
not differ significantly among subjects with or without GDM (p>0.05).

Conclusions: Although SeP plays a key role in glucose metabolism
and the regulation of insulin sensitivity, the SEPP1 polymorphism did not
changed occurrence of GDM in our population. Different mechanisms may be
involved in etiopathogenesis of GDM. However, it should be clarified with
further studies in larger populations. SEPP1 (rs3877899) polymorphism has no
role in development of gestational diabetes in Turkish women.

Anahtar Kelimeler

Gestational diabetes mellitus; Selenoprotein P gene; Polymorphism

Kaynakça

• 1. Metzger BE, Coustan DR. Summary and recommendations of the fourth international workshop-conference on gestational diabetes mellitus. The Organizing Committee. Diabetes Care 1998; 21: B161–7.
• 2. Catalano PM, Kirwan JP, Haugel-de Mouzon S, King J. Gestational diabetes and insulin resistance: role in short- and long-term implications for mother and fetus. J Nutr 2003; 133: 1674S–83S.
• 3. Yan M, Mehta JL, Zhang W, Hu C. LOX-1, oxidative stress and inflammation: a novel mechanism for diabetic cardiovascular complications. Cardiovasc Drugs Ther 2011; 25(5): 451–59.
• 4. Meplan C, Crosley LK, Nicol F, Beckett GJ, et al. Genetic polymorphisms in the human selenoprotein P gene determine the response of selenoprotein markers to selenium supplementation in a gender-specific manner (the SELGEN study). Faseb J 2007; 21: 3063–74.
• 5. Meplan C, Nicol F, Burtle BT, Crosley LK, et al. Relative abundance of selenoprotein P isoforms in human plasma depends on genotype, Se intake, and cancer status. Antioxid Redox Signal 2009; 11: 2631–40.
• 6. Cooper ML, Adami HO, Gronberg H, Wiklund F, Green FR, et al. Interaction between single nucleotide polymorphisms in selenoprotein P and mitochondrial superoxide dismutase determines prostate cancer risk. Cancer Res 2008; 68: 10171–177.
• 7. Meplan C, Hughes DJ, Pardini B, Naccarati A, et al. Genetic variants in selenoprotein genes increase risk of colorectal cancer. Carcinogenesis 2010; 31: 1074–1079.
• 8. Steinbrecher A, Meplan C, Hesketh J, Schomburg L, et al. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiol Biomarkers Prev 2010; 19: 2958–68.
• 9. Karunasinghe N, Han DY, Zhu S, Yu J, et al. Serum selenium and single-nucleotide polymorphisms in genes for selenoproteins: relationship to markers of oxidative stress in men from Auckland, New Zealand. Genes Nutr. 2012; 7: 179–90.
• 10. Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol 1982; 144:768–73.
• 11. Altinova AE, Iyidir OT, Ozkan C, et al. Selenoprotein P is not elevated in gestational diabetes mellitus. Gynecol Endocrinol. 2015; 31(11): 874-6.
• 12. Farhan S, Handisurya A, Todoric J, et al. Fetuin-A characteristics during and after pregnancy: result from a case control pilot study. Int J Endocrinol 2012; 2012: 896736.
• 13. Stein S, Stepan H, Kratzsch J, et al. Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metabolism 2010; 59: 33–7.
• 14. Misu H, Takamura T, Takayama H, et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab 2010; 12: 483–95.
• 15. Yang SJ, Hwang SY, Choi HY, et al. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. J Clin Endocrinol Metab 2011; 96: E1325–9.
• 16. Roman M, Lapolla A, Jitaru P, et al. Plasma selenoproteins concentrations in type 2 diabetes mellitus – a pilot study. Transl Res 2010; 156: 242–50.
• 17. Meplan C, Dragsted LO, Ravn-Haren G, et al. Association between polymorphisms in glutathione peroxidase and selenoprotein P genes, glutathione peroxidase activity, HRT use and breast cancer risk. PLoS One. 2013;10; 8(9):e73316.
• 18. Cooper ML, Adami HO, Gronberg H, Wiklund F, Green FR, et al. (2008) Interaction between single nucleotide polymorphisms in selenoprotein P and mitochondrial superoxide dismutase determines prostate cancer risk. Cancer Res 2008; 68: 10171–77.